CY1867A - Use of benzimidazoles in the treatment of epithelial disorders - Google Patents

Use of benzimidazoles in the treatment of epithelial disorders

Info

Publication number
CY1867A
CY1867A CY186796A CY186796A CY1867A CY 1867 A CY1867 A CY 1867A CY 186796 A CY186796 A CY 186796A CY 186796 A CY186796 A CY 186796A CY 1867 A CY1867 A CY 1867A
Authority
CY
Cyprus
Prior art keywords
effective amount
benzimidazoles
treatment
isomeric form
stereochemically isomeric
Prior art date
Application number
CY186796A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1867A publication Critical patent/CY1867A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/496—Triazoles or their condensed derivatives, e.g. benzotriazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY186796A 1988-11-29 1996-04-05 Use of benzimidazoles in the treatment of epithelial disorders CY1867A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27715288A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
CY1867A true CY1867A (en) 1996-04-05

Family

ID=23059616

Family Applications (1)

Application Number Title Priority Date Filing Date
CY186796A CY1867A (en) 1988-11-29 1996-04-05 Use of benzimidazoles in the treatment of epithelial disorders

Country Status (16)

Country Link
EP (2) EP0609963B1 (fr)
JP (2) JP2752200B2 (fr)
AT (2) ATE112681T1 (fr)
AU (2) AU623454B2 (fr)
CA (1) CA2002859C (fr)
CY (1) CY1867A (fr)
DE (2) DE68929377T2 (fr)
DK (1) DK175793B1 (fr)
ES (2) ES2065369T3 (fr)
HK (1) HK114895A (fr)
IE (1) IE63877B1 (fr)
IL (1) IL92487A (fr)
NZ (1) NZ231405A (fr)
PT (1) PT92449B (fr)
SG (1) SG50466A1 (fr)
ZA (1) ZA899074B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002859C (fr) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales
PL176059B1 (pl) * 1992-11-10 1999-03-31 Janssen Pharmaceutica Nv Sposób wytwarzania enancjomerycznie czystego 6-[(4-chlorofenylo) (1H-1,2,4-triazol-1-ilo)-metylo]-1-metylo-1H-benzotriazolu
CN1141042A (zh) * 1994-02-18 1997-01-22 詹森药业有限公司 旋光对映纯的(+)-利罗唑
TW418203B (en) * 1994-02-18 2001-01-11 Janssen Pharmaceutica Nv Enantiomerically pure (-)-liarozole
EP0800391A1 (fr) * 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazoles utilises comme inhibiteurs du metabolisme du calcitriol
TW316902B (fr) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
WO1997006788A1 (fr) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Administration trans-cutanee de vorozole
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
KR100365312B1 (ko) * 1996-06-27 2003-03-06 얀센 파마슈티카 엔.브이. N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민
JPH10220909A (ja) 1996-12-03 1998-08-21 Komatsu Ltd 流体温度制御装置
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
JP2001525400A (ja) 1997-12-11 2001-12-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ レチノイン酸擬似アニリド
JP2002518387A (ja) * 1998-06-16 2002-06-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
WO2000066077A1 (fr) * 1999-04-29 2000-11-09 Avon Products, Inc. Methode pour ameliorer l'aspect esthetique de l'epithelium
EP1420015A1 (fr) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Dérivés de l'imidazole
FR2815857B1 (fr) * 2000-10-30 2003-02-14 Oreal Composition, notamment cosmetique, renfermant un retinoide et une silicone benzotriazole
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP2006513162A (ja) * 2002-11-01 2006-04-20 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用方法
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
BR112012016398B1 (pt) 2009-12-30 2021-12-21 Arqule, Inc Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
WO2012177852A1 (fr) 2011-06-24 2012-12-27 Arqule, Inc Composés d'imidazopyridinyle substitués
KR20190015600A (ko) 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859684A (en) * 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
NZ224714A (en) * 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
CA2002859C (fr) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Methode de traitement d'affections epitheliales

Also Published As

Publication number Publication date
JPH0320273A (ja) 1991-01-29
AU4564889A (en) 1990-06-07
DE68929377T2 (de) 2002-10-31
DK175793B1 (da) 2005-02-21
DK599589D0 (da) 1989-11-28
DK599589A (da) 1990-05-30
ATE213941T1 (de) 2002-03-15
NZ231405A (en) 1991-08-27
CA2002859C (fr) 1998-12-29
JP2752200B2 (ja) 1998-05-18
JP2912596B2 (ja) 1999-06-28
EP0609963B1 (fr) 2002-03-06
PT92449B (pt) 1995-07-18
IL92487A (en) 1994-12-29
IE950033L (en) 1990-05-29
DE68918809T2 (de) 1995-03-23
IE63877B1 (en) 1995-06-14
SG50466A1 (en) 1998-07-20
IL92487A0 (en) 1990-08-31
AU623454B2 (en) 1992-05-14
ES2065369T3 (es) 1995-02-16
CA2002859A1 (fr) 1990-05-29
ES2173902T3 (es) 2002-11-01
EP0609963A1 (fr) 1994-08-10
EP0371559A3 (fr) 1992-04-08
DE68918809D1 (de) 1994-11-17
JPH1095782A (ja) 1998-04-14
EP0371559B1 (fr) 1994-10-12
AU630579B2 (en) 1992-10-29
ATE112681T1 (de) 1994-10-15
ZA899074B (en) 1991-07-31
IE893781L (en) 1990-05-29
HK114895A (en) 1995-07-21
EP0371559A2 (fr) 1990-06-06
DE68929377D1 (de) 2002-04-11
PT92449A (pt) 1990-05-31
AU1071692A (en) 1992-03-19

Similar Documents

Publication Publication Date Title
HK114895A (en) Use of benzimidazoles in the treatment of epithelial disorders
DK0570594T3 (fr)
PL268455A1 (en) The method of manufacture of new derivatives of benzimidazole
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
ES8707947A1 (es) Un procedimiento para la preparacion de acidos 3-hidroxifenoxialquilenheterociclilcarboxilicos.
DE69430816D1 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
ES2001703A6 (es) Procedimiento para la preparracion de derrrivados de acidos 2-(2-imidazolin -2-il)- piridin -3- carboxilicos.
ATE242220T1 (de) Benzimidazolderivate mit dopaminerger wirkung
DE3786865D1 (de) Aminosaeurederivate enthaltende antikonvulsive zusammensetzungen und verwendung dieser aminosaeurederivate.
ATE73330T1 (de) Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen.
MX9603316A (es) (+)-liarozol enantiomericamente puro.
ATE167869T1 (de) Thiolderivate von gallensäure
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
JPS6452772A (en) Pyridylpyrimidine derivative, production thereof and plant disease controlling agent containing said derivative as active ingredient
DE3168004D1 (en) Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof
AU2013888A (en) Uricosuric composition
MX9603510A (es) (-)-liarozol enantiomericamente puro.
ES8606375A1 (es) Un procedimiento para preparar un derivado de aminoprpilaminobleomicina